573 related articles for article (PubMed ID: 27507892)
1. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathy.
Madden B; Singh RD; Haas M; Palma LMP; Sharma A; Vargas MJ; Gross L; Negron V; Nate T; Charlesworth MC; Theis JD; Nasr SH; Nath KA; Fervenza FC; Sethi S
Kidney Int; 2024 May; 105(5):1077-1087. PubMed ID: 38447879
[TBL] [Abstract][Full Text] [Related]
3. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
4. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
5. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
6. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study.
Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH
Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915
[TBL] [Abstract][Full Text] [Related]
7. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren inhibits renin-mediated complement activation.
Békássy ZD; Kristoffersson AC; Rebetz J; Tati R; Olin AI; Karpman D
Kidney Int; 2018 Oct; 94(4):689-700. PubMed ID: 29884545
[TBL] [Abstract][Full Text] [Related]
9. Distribution of activated complement, C3b, and its degraded fragments, iC3b/C3dg, in the colonic mucosa of ulcerative colitis (UC).
Ueki T; Mizuno M; Uesu T; Kiso T; Nasu J; Inaba T; Kihara Y; Matsuoka Y; Okada H; Fujita T; Tsuji T
Clin Exp Immunol; 1996 May; 104(2):286-92. PubMed ID: 8625522
[TBL] [Abstract][Full Text] [Related]
10. C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition.
Sethi S; Quint PS; O'Seaghdha CM; Fervenza FC; Bijol V; Dorman A; Dasari S; Smith RJ; Kurtin PJ; Rennke HG
Am J Kidney Dis; 2016 Jun; 67(6):949-53. PubMed ID: 26896898
[TBL] [Abstract][Full Text] [Related]
11. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
12. Alternative pathway dysfunction in kidney disease: a case report and review of dense deposit disease and C3 glomerulopathy.
Hawfield A; Iskandar SS; Smith RJ
Am J Kidney Dis; 2013 May; 61(5):828-31. PubMed ID: 23391537
[TBL] [Abstract][Full Text] [Related]
13. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
14. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
[TBL] [Abstract][Full Text] [Related]
15. Pathology after eculizumab in dense deposit disease and C3 GN.
Herlitz LC; Bomback AS; Markowitz GS; Stokes MB; Smith RN; Colvin RB; Appel GB; D'Agati VD
J Am Soc Nephrol; 2012 Jul; 23(7):1229-37. PubMed ID: 22677550
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
19. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
West CD; McAdams AJ
Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
[TBL] [Abstract][Full Text] [Related]
20. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.
Yang Y; Denton H; Davies OR; Smith-Jackson K; Kerr H; Herbert AP; Barlow PN; Pickering MC; Marchbank KJ
J Am Soc Nephrol; 2018 Jun; 29(6):1649-1661. PubMed ID: 29588430
[No Abstract] [Full Text] [Related]
[Next] [New Search]
